Business Description
Teva Pharmaceutical Industries Ltd
NAICS : 325412
ISIN : US8816242098
Share Class Description:
HAM:TEV: ADRCompare
Compare
Traded in other countries / regions
TEVA.USATEVA.Israel0LER.UKTEV.GermanyTEVA.MexicoTEVA.AustriaT1EV34.Brazil IPO Date
2007-11-02Description
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.16 | |||||
| Equity-to-Asset | 0.17 | |||||
| Debt-to-Equity | 2.69 | |||||
| Debt-to-EBITDA | 12.94 | |||||
| Interest Coverage | 3.1 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 0.21 | |||||
| Beneish M-Score | -2.47 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -2.4 | |||||
| 3-Year EPS without NRI Growth Rate | -0.1 | |||||
| 3-Year FCF Growth Rate | 8.9 | |||||
| 3-Year Book Growth Rate | -9.9 | |||||
| Future 3-5Y Total Revenue Growth Rate | 1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 57.83 | |||||
| 9-Day RSI | 49.1 | |||||
| 14-Day RSI | 48.88 | |||||
| 6-1 Month Momentum % | 67.75 | |||||
| 12-1 Month Momentum % | 73.13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.02 | |||||
| Quick Ratio | 0.69 | |||||
| Cash Ratio | 0.26 | |||||
| Days Inventory | 179.18 | |||||
| Days Sales Outstanding | 80.45 | |||||
| Days Payable | 103.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.7 | |||||
| Shareholder Yield % | 11.03 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 48.24 | |||||
| Operating Margin % | 20.14 | |||||
| Net Margin % | -3.53 | |||||
| FCF Margin % | 5.21 | |||||
| ROE % | -7.52 | |||||
| ROA % | -1.29 | |||||
| ROIC % | 8.33 | |||||
| ROC (Joel Greenblatt) % | 6.61 | |||||
| ROCE % | 1.28 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 5.43 | |||||
| PE Ratio without NRI | 5.04 | |||||
| PS Ratio | 0.91 | |||||
| PB Ratio | 1.92 | |||||
| Price-to-Free-Cash-Flow | 17.11 | |||||
| Price-to-Operating-Cash-Flow | 10.55 | |||||
| EV-to-EBIT | 77.23 | |||||
| EV-to-Forward-EBIT | 19.63 | |||||
| EV-to-EBITDA | 20.08 | |||||
| EV-to-Forward-EBITDA | 8.57 | |||||
| EV-to-Revenue | 1.97 | |||||
| EV-to-Forward-Revenue | 1.98 | |||||
| EV-to-FCF | 37.13 | |||||
| Price-to-Projected-FCF | 1.02 | |||||
| Price-to-Median-PS-Value | 1.23 | |||||
| Earnings Yield (Greenblatt) % | 1.3 | |||||
| FCF Yield % | 5.77 | |||||
| Forward Rate of Return (Yacktman) % | 22.42 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers